120 related articles for article (PubMed ID: 11504367)
1. Results of a prospective study with high-dose etoposide, thiotepa and carboplatin and peripheral blood stem cell rescue for high-risk stage II-IIIA and selected stage IV breast cancer patients.
Gori S; Mosconi AM; Tabilio A; Falzetti F; Aristei C; Basurto C; Cherubini R; Latini P; Martelli MF; Tonato M; Colozza M
Tumori; 2001; 87(3):138-41. PubMed ID: 11504367
[TBL] [Abstract][Full Text] [Related]
2. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
3. T1-T2 breast cancer with four or more positive axillary lymph nodes: adjuvant locoregional radiotherapy with high-dose or standard-dose chemotherapy. Results of an observational study.
Perrucci E; Aristei C; De Angelis V; Anselmo P; Mascioni F; Gori S; Frattegiani A; Latini P
Tumori; 2004; 90(4):379-86. PubMed ID: 15510979
[TBL] [Abstract][Full Text] [Related]
4. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
5. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
6. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
[TBL] [Abstract][Full Text] [Related]
7. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
Fields KK; Elfenbein GJ; Perkins JB; Ballester OF; Goldstein SC; Heimenz JW; Saez RA; Sullivan DM; Partyka JS; Kronish LA
Semin Oncol; 1998 Apr; 25(2 Suppl 4):1-6; discussion 45-8. PubMed ID: 9578055
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer.
Kuzhan O; Ozet A; Ulutin C; Kömürcü S; Arpaci F; Oztürk B; Oztürk M
Tumori; 2007; 93(6):550-6. PubMed ID: 18338488
[TBL] [Abstract][Full Text] [Related]
10. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
[TBL] [Abstract][Full Text] [Related]
11. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
[TBL] [Abstract][Full Text] [Related]
12. Durable remission of locally advanced breast cancer with multimodality management.
Miller A; Khosla P; Lynch J; Moreb J; Cullins S; Safah H; Hutchison C; La Russa V; Vellis K; Rice J; Mendenhall N; Weiner R
Med Oncol; 1998 Jul; 15(2):89-95. PubMed ID: 9789215
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT; Papadopoulos K; Balmaceda C; McGovern T; Dunleavy J; Kaufman E; Fung B; Garrett T; Savage D; Tiersten A; Ayello J; Bagiella E; Heitjan D; Antman K; Hesdorffer C
Clin Cancer Res; 1998 Jul; 4(7):1689-95. PubMed ID: 9676843
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers.
Schwartzberg LS; Birch R; West WH; Tauer KW; Wittlin F; Leff R; Campos L; Rymer W; Carter P; Mangum M; Greco FA; Hainsworth J; Raefsky E; Blanco R; Buckner CD; Weaver CH
Am J Clin Oncol; 1998 Oct; 21(5):523-31. PubMed ID: 9781614
[TBL] [Abstract][Full Text] [Related]
17. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
18. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
19. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
20. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
